Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers Meeting Abstract
| Authors: | Johnson, M. L.; Dy, G. K.; Mamdani, H.; Dowlati, A.; Schoenfeld, A. J.; Pacheco, J. M.; Sanborn, R. E.; Menon, S. P.; Santiago, L.; Yaron, Y.; Beltran, H. |
| Abstract Title: | Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680302168 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.8566 |
| Notes: | Meeting Abstract: 8566 -- Meeting also held virtually -- Source: Wos |
